Hemostemix Inc. received full approval from The Bahamas' National Longevity and Regenerative Therapy Board for its Phase 1 commercial study of VesCell™, targeting angina, vascular dementia, and pain. This approval integrates Hemostemix into The Bahamas' regenerative medicine sector alongside other biotech firms. The company is also raising up to C$1 million through a private placement to support manufacturing and clinical programs. Hemostemix plans a second study on VesCell™ for longevity benefits, focusing on cognition, heart function, and immune health improvements.
Hemostemix's recent developments provide context for readers. For those tracking health-sector stocks, 57 of 100 US stocks rose and 43 fell on Pluang. Notable movers include HRTX at USD 0.39 with a +17.27% change and 70% buy activity, FLNA at USD 0.80 down 8.65%, and DNA at USD 11.61 down 6.45%. Data is as of Oct 08, 2026 01:31 WIB.
Delta Air Lines is set to report its Q3 2026 earnings with mixed analyst expectations amid rising fuel costs, refinery outages, and higher labor expenses. While travel demand remains strong, these cost pressures are expected to weigh on profits. Inve...
Constellation Brands reported strong Q2 fiscal 2027 earnings of $3.74 per share, beating estimates and showing a 3% year-over-year increase. Net sales rose 6% to $2.63 billion, driven by 5% growth in beer sales and 17% in wine and spirits. Despite th...
SCWorx Corp. has resumed trading on the Nasdaq Capital Market on October 7, 2026, after a suspension that began in April. The company successfully reversed a delisting decision by regaining compliance with Nasdaq's minimum bid price and publicly held...
Star Bulk Carriers' Chief Operating Officer, Reskos, purchased 10,000 shares at $28.27 each. This insider buying signals confidence in the company's prospects and may encourage investors to consider buying SBLK stock. The move could indicate positive...
Twilio's stock has surged 97% this year, driven by accelerating gross profit growth and rising interest in its voice AI technology. Investors are focused on whether the company can sustain or increase its gross profit growth in the upcoming third qua...
